Our new report examines current and future prospects for the age-related macular degeneration (AMD) and diabetic retinopathy (DR) pharmaceutical markets. The global market for AMD and DR drugs exceeded $2.5bn in 2009, with growth from previous years. We predict that the overall market will expand from 2010 onwards. The rising prevalence of AMD and DR is due to aging populations worldwide and other changes. In particular, the world is facing a "diabetes epidemic", with soaring numbers of people with diabetes and related complications, including diabetic retinopathy.

In particular, Macular Degeneration (AMD) and Diabetic Retinopathy Pharmaceutical Market 2010-2025 covers market prospects for the following agents:
• Lucentis
• Visudyne
• Macugen
• Avastin.

Our report examines prospects for the retinal disorders market over the coming 15 years. The commercial success of Lucentis in treating wet AMD illustrates the high rewards for successful treatments. Our analyses reveal that there are commercial opportunities for the treatment of geographic atrophy (advanced dry AMD) and for wet AMD, among other disorders. There is a need for advantages over existing therapies, for improved clinical outcomes and ease of dosing. A large potential market for pharmacological treatment of diabetic retinopathy, AMD and other retinal disorders exists.

Un-met and under-met therapeutic needs provide an impetus to drug developers, with high technological and commercial potential in this sector, our study reveals. What impact will monoclonal antibodies and steroid implants have on the future market? Which products are most likely to meet therapeutic needs in future years? Can newer therapies compete successfully with established treatments? How will Avastin affect the market share of Lucentis, and what are the implications for the future market? Our new report covers such questions, providing the information that you need.

Comprehensive analysis of the global AMD and DR sectors

Macular Degeneration (AMD) and Diabetic Retinopathy Pharmaceutical Market 2010-2025 examines those sectors through a comprehensive review of information sources. We harness primary and secondary research. This report provides unique sales forecasts, market share analyses, discussions of R&D pipeline developments and analyses of commercial drivers and restraints, including a SWOT analysis. There are over 75 tables and figures included, as well as three interviews with industry experts. The result is a comprehensive market- and industry-centred study, with detailed analyses and informed opinion to benefit your work.


Report Highlights
Companies Listed
Alcon (Nestlé)
Alimera Sciences
Allergan
American Academy of Ophthalmology (AAO)
American Society of Retinal Specialists (ASRS)
Association for Research in Vision and Ophthalmology (ARVO)
AstraZeneca
Bausch & Lomb
Bayer
BioDiem
Bristol-Myers Squibb
British Medical Journal (BMJ)
Centers for Medicare and Medicaid Services (CMS) [US]
Centre for Molecular and Vascular Biology, KU Leuven
Chugai
CoMentis
Diabetic Retinopathy Clinical Research Network (DRCR) [US]
Eli Lilly
Emory University
ESBATech
Esteve
European Medicines Agency (EMEA)
Eyetech (acquired by OSI Pharmaceuticals, 2005)
Eyetech (corporation formed in 2008)
Food and Drug Administration (FDA) [US]
Fovea
Gene Signal
Genentech (acquired by Roche, 2009)
GenVec
Gilead
GlaxoSmithKline (GSK)
iCo
Isis
Jerini Ophthalmic
KAI Pharmaceuticals
Lpath
Ludwig-Maximilians-Universität [Germany]
MacuSight
Medicare
Merck & Co.
Moorfields Eye Hospital [UK]
National Eye Institute (NEI), part of the National Institutes of Health (NIH) [US]
National Health Service (NHS) [UK]
National Institute for Health and Clinical Excellence (NICE) [UK]
National Institute for Health Research (NIHR) [UK]
National Institutes of Health (NIH) [US]
Neurotech
NeXstar (acquired by Gilead, 1999)
Novartis
OM Pharmaceuticals
Ophthotech
Opko
OSI Pharmaceuticals
Othera Pharmaceuticals
Oxford BioMedica
Oxigene
Pfizer
Pharmaceutical Benefits Service (PBS) [Australia]
Potentia
pSivida
QLT
Quark
Regeneron
Retinagenix
Roche
Santen
Sanwa Kagaku Kenkyusho (subsidiary of Suzuken)
Shire
Sirion Therapeutics
Sirna Therapeutics
Sirnaomics
Suzuken
Symphony ViDA
Takeda
TargeGen
Targeted Genetics
ThromboGenics
University College London
University of Florida
University of Kentucky College of Medicine
US Census Bureau
Vitreoretinal Technologies
World Health Organization (WHO)
Wyeth (now part of Pfizer)
[Studien Infos ausblenden]

1. Executive Summary
1.1 AMD & Diabetic Retinopathy Market Review
1.2 Aim, Scope and Format of the Report
1.3 Chapter Outlines
1.4 Research and Analysis Methods

2. Macular Degeneration and Diabetic Retinopathy
2.1 Vision
2.1.1 The Human Eye
2.1.2 The Retina and the Vision Process
2.2 Age-Related Macular Degeneration (AMD)
2.2.1 Early Stages of AMD
2.2.2 Advanced Dry AMD (Geographic Atrophy)
2.2.3 Wet AMD
2.2.4 Causes and Risk Factors for AMD
2.3 Diabetic Retinopathy (DR)
2.3.1 Causes and Types of Diabetic Retinopathy
2.3.2 Non-Proliferative Diabetic Retinopathy
2.3.3 Diabetic Macular Oedema
2.3.4 Proliferative Diabetic Retinopathy (PDR)
2.3.5 Risk Factors for Diabetic Retinopathy
2.4 Diagnosis
2.5 Epidemiology
2.6 Other Retinal Disorders

3. The World Market for AMD and Diabetic Retinopathy Drugs
3.1 World AMD and DR Market Forecasts 2010-2025
3.2 AMD Market Forecast 2010-2025
3.3 Diabetic Retinopathy Market
3.4 Market Shares
3.5 Leading Companies in the Sector

4. Treatments for AMD and Diabetic Retinopathy
4.1 Treatment of Wet AMD
4.1.1 Visudyne
4.1.1.1 Visudyne: Forecast and Analysis 2010-2025
4.1.2 Macugen
4.1.2.1 Macugen: Forecast and Analysis 2010-2025
4.1.3 Retaane
4.1.4 Lucentis
4.1.4.1 Lucentis: Forecast and Analysis 2010-2025
4.1.5 Avastin
4.1.5.1 Avastin: Forecast and Analysis 2010-2025
4.2 Treatment of Dry AMD
4.2.1 Nutritional Supplements
4.2.2 Intraocular Lenses
4.3 Treatments for Diabetic Retinopathy
4.3.1 Laser and Other Surgical Treatments
4.3.2 Triamcinolone Acetonide
4.3.3 Lisinopril
4.3.4 VEGF Inhibitors
4.3.5 Dobesilate

5. AMD and Diabetic Retinopathy: Leading National Markets
5.1 US: Sales Prospects 2010-2025
5.2 France: Sales Prospects 2010-2025
5.3 Japan: Sales Prospects 2010-2025
5.4 Germany: Sales Prospects 2010-2025
5.5 UK: Sales Prospects 2010-2025
5.6 Spain: Sales Prospects 2010-2025
5.7 Australia: Sales Prospects 2010-2025
5.8 Canada: Sales Prospects 2010-2025
5.9 China: Sales Prospects 2010-2025
5.10 India: Sales Prospects 2010-2025
5.11 Comparing the National Markets

6. Issues Affecting the AMD and DR Pharmaceutical Markets
6.1 SWOT Analysis of the AMD and DR Pharmaceutical Markets
6.2 Intense Research and Development Activity
6.2.1 New Drug Formulations
6.2.2 Sustained-Release Ocular Implants
6.2.3 Novel Biologic Drugs
6.2.4 New Ophthalmic Therapeutic Applications for Drugs
6.3 The Avastin-Lucentis Debate
6.3.1 Avastin and Lucentis
6.3.2 Off-Label Retinal Applications of Avastin
6.3.3 History of Avastin Use for Wet AMD
6.3.4 The CATT Study
6.3.5 The Future for Off-Label Avastin Use
6.4 Aging of the World Population Increases Demand for Treatments
6.5 Prevalence of Retinal Disorders
6.5.1 Prevalence of AMD in 2009
6.5.2 AMD Prevalence 2009-2025
6.5.3 Prevalence of Diabetes, Proliferative Diabetic Retinopathy and Diabetic Macular Oedema, 2009
6.5.4 Prevalence of Diabetic Retinopathy 2009-2025
6.6 Reimbursement for AMD and Diabetic Retinopathy Pharmaceuticals
6.6.1 Pressure on Healthcare in Current Difficult Economic Environment
6.6.2 Prospects for Reimbursement for AMD and DR Drugs
6.7 Diagnosis and Screening for Retinal Disorders
6.8 Laser and Surgical Treatments for Diabetic Retinopathy Will Compete with New Drugs
6.8.1 Current Laser Treatments
6.8.2 Will Drugs Replace Laser Therapy?

7. The AMD and Diabetic Retinopathy R&D Pipelines
7.1 VEGF Trap-Eye/Aflibercept (Regeneron/Bayer)
7.2 Ozurdex/SK-0503 (Allergan/Sanwa Kagaku Kenkyusho)
7.3 Bevasiranib (Opko)
7.4 Avastin and Lucentis Comparison Trials (CATT)
7.5 PF-4523655 (Quark/Pfizer)
7.6 Votrient (pazopanib) (GSK)
7.7 Zybrestat (Oxigene/Symphony ViDA)
7.8 Sirolimus (MacuSight/Santen)
7.9 Iluvien (Alimera/pSivida)
7.10 NT-501 (Neurotech)
7.11 OT-551 (Othera)
7.12 Lucentis (Novartis)
7.13 Macugen (Pfizer)
7.14 Vitreosolve (Vitreoretinal Technologies)
7.15 Microplasmin (ThromboGenics)
7.16 Arxxant (ruboxistaurin, Eli Lilly/Alcon/Takeda)
7.17 Stem Cells

8. Opinion from Industry Experts
8.1 Edward Danse, President and CEO, Neurotech
8.1.1 Retinal Disorders with Greatest Unmet Patient Need
8.1.2 Neurotech's AMD Pipeline
8.1.3 Progress of NT-501 Clinical Trials in Geographic Atrophy Patients
8.1.4 Screening Programmes for AMD
8.1.5 Potential Lifetime of NT-501 in the Eye
8.1.6 Other Potential Treatments for Geographic Atrophy
8.1.7 Potential Use of NT-501 in Diabetic Retinopathy
8.2 Ken Green, Ph.D., Chief Scientific Officer, and Dave Holland, Founder/VP Marketing, Alimera Sciences
8.2.1 Main Unmet Clinical Needs Among Diabetic Retinopathy Patients
8.2.2 Development of Iluvien for Diabetic Macular Oedema
8.2.3 Reimbursement Prospects for Corticosteroid Inserts
8.2.4 Future for Laser Therapy in Diabetic Retinopathy
8.2.5 Possible Future Treatment for Dry AMD and Geographic Atrophy
8.2.6 Clinical Trials of Iluvien for Wet AMD and RVO
8.3 Dr Al Reaves, Ph.D., Senior Vice President of Clinical Development, Othera Pharmaceuticals
8.3.1 Othera's Geographic Atrophy Drug: OT-551
8.3.2 New Drugs for Retinal Disorders Currently with No Treatments

9. Conclusions
9.1 AMD and Diabetic Retinopathy
9.2 Increasing Prevalence of AMD and Diabetic Retinopathy
9.3 Current Treatments for AMD and Diabetic Retinopathy
9.4 The AMD and DR Pharmaceutical Market in 2009
9.5 AMD and Diabetic Retinopathy Pharmaceutical Market Forecast, 2010-2025
9.6 Lucentis Market Forecast, 2010-2025
9.7 The AMD R&D Pipeline
9.8 The Diabetic Retinopathy R&D Pipeline
9.9 Concluding Remarks
[Inhaltsverzeichnis ausblenden]

Table 2.1 Causes of Blindness Worldwide, 2007
Table 2.2 Wet AMD Types
Table 2.3 AMD and DR Diagnosis Methods
Table 2.4 Incidence and Prevalence of Advanced AMD & DR, 2009
Table 2.5 Cases of Advanced AMD by Age Group, 2009
Table 2.6 Cases of AMD by Age Group, 2009
Table 2.7 Cases of DR by Age Group, 2009
Table 2.8 Other Retinal Disorders
Table 3.1 AMD & DR Pharmaceutical Markets, 2009
Table 3.2 AMD and DR Markets: Revenue Forecasts, 2010-2025
Table 3.3 AMD Pharmaceutical Market: Revenue Forecast, 2010-2025
Table 3.4 DR Pharmaceutical Market: Revenue Forecast, 2010-2025
Table 3.5 AMD and DR: Market Shares, 2010-2025
Table 3.6 AMD & DR Pharmaceutical Markets: Leading Companies, 2009
Table 4.1 AMD and DR Pharmaceutical Markets: Revenue Forecasts, 2010-2025
Table 4.2 Visudyne Sales Breakdown, 2009
Table 4.3 Visudyne: Revenue Forecast, 2010-2025
Table 4.4 Macugen: Revenue Forecast, 2010-2025
Table 4.5 Lucentis: Regulatory Approval and Launch Dates
Table 4.6 Lucentis: Revenue Forecast, 2010-2025
Table 4.7 Avastin: Revenue Forecast, 2010-2025
Table 5.1 AMD & DR Market: Sales in Leading National Markets, 2009
Table 5.2 The US AMD & DR Market: Revenue Forecast, 2010-2025
Table 5.3 French AMD & DR Market: Revenue Forecast, 2010-2025
Table 5.4 Proportion of Leading Markets’ Populations over 65, 2010 and 2030
Table 5.5 Japanese AMD & DR Market: Revenue Forecast, 2010-2025
Table 5.6 German AMD & DR Market: Revenue Forecast, 2010-2025
Table 5.7 UK AMD & DR Market: Revenue Forecast, 2010-2025
Table 5.8 Spanish AMD & DR Market: Revenue Forecast, 2010-2025
Table 5.9 Australian AMD & DR Market: Revenue Forecast, 2010-2025
Table 5.10 Canadian AMD & DR Market: Revenue Forecast, 2010-2025
Table 5.11 Chinese AMD & DR Market: Revenue Forecast, 2010-2025
Table 5.12 Indian AMD & DR Market: Revenue Forecast, 2010-2025
Table 5.13 Comparison of Leading National Markets: Revenue Forecasts, 2010-2025
Table 6.1 SWOT Analysis of Age-Related Macular Degeneration & Diabetic Retinopathy Pharmaceutical Market, 2010
Table 6.2 World Population Aging, 2009-2025
Table 6.3 Number of Over-60s in Selected Countries, 2009 and 2025
Table 6.4 AMD Incidence, 2009-2025
Table 6.5 DR Incidence, 2009-2025
Table 7.1 Key Late-Stage AMD Pipeline Drugs, 2010
Table 7.2 Selected Early-Stage AMD Pipeline Drugs, 2010
Table 7.3 Lucentis Clinical Trials in Progress, 2010
Table 7.4 Key Late-Stage Diabetic Retinopathy Pipeline Drugs, 2010
Table 7.5 Selected Early-Stage DR Pipeline Drugs, 2010
Table 9.1 AMD & DR: Incidence Rates, 2009 and 2025

Figure 2.1 Leading Causes of Blindness Worldwide, 2007
Figure 2.2 How AMD Progresses
Figure 2.3 Incidence and Prevalence of Advanced AMD & DR, 2009
Figure 2.4 Proportion of Advanced AMD Cases by Age Group, 2009
Figure 2.5 Proportion of AMD Cases by Gender, 2009
Figure 2.6 Cases of DR by Age Group, 2009
Figure 3.1 AMD and DR Pharmaceutical Markets, 2009
Figure 3.2 AMD and DR Markets: Revenue Forecasts, 2010-2025
Figure 3.3 AMD Pharmaceutical Market: Revenue Forecast, 2010-2025
Figure 3.4 DR Pharmaceutical Market: Revenue Forecast, 2010-2025
Figure 3.5 AMD and DR: Market Shares, 2010-2025
Figure 3.6 AMD and DR Pharmaceutical Markets: Leading Companies, 2009
Figure 4.1 Visudyne: Sales Breakdown, 2009
Figure 4.2 Visudyne: Revenue Forecast, 2010-2025
Figure 4.3 Macugen: Revenue Forecast, 2010-2025
Figure 4.4 Lucentis: Revenue Forecast, 2010-2025
Figure 4.5 Avastin: Revenue Forecast, 2010-2025
Figure 5.1 AMD & DR Market Shares of Ten Leading Countries, 2009
Figure 5.2 US AMD & DR Market: Revenue Forecast, 2010-2025
Figure 5.3 Proportion of Leading Markets’ Populations Aged over 65, 2010 and 2030
Figure 5.4 French AMD & DR Market: Revenue Forecast, 2010-2025
Figure 5.5 Japanese AMD & DR Market: Revenue Forecast, 2010-2025
Figure 5.6 German AMD & DR Market: Revenue Forecast, 2010-2025
Figure 5.7 UK AMD & DR Market: Revenue Forecast, 2010-2025
Figure 5.8 Spanish AMD & DR Market: Revenue Forecast, 2010-2025
Figure 5.9 Australian AMD & DR Market: Revenue Forecast, 2010-2025
Figure 5.10 Canadian AMD & DR Market: Revenue Forecast, 2010-2025
Figure 5.11 Chinese AMD & DR Market: Revenue Forecast, 2010-2025
Figure 5.12 Indian AMD & DR Market: Revenue Forecast, 2010-2025
Figure 5.13 Leading Country Markets (Upper Tier): Revenue Forecasts, 2010-2025
Figure 5.14 Leading Country Markets (Lower Tier): Revenue Forecasts, 2010-2025
Figure 6.1 World Population Aging, 2009-2025
Figure 6.2 Number of Over-60s in Selected Countries, 2009 and 2025
Figure 6.3 AMD Incidence, 2009-2025
Figure 6.4 Diabetic Retinopathy Incidence Forecast, 2009 and 2025
Figure 9.1 World AMD & DR Pharmaceutical Market Forecasts, 2010-2025
Figure 9.2 Lucentis: Revenue Forecast, 2010-2025
[Tabellenverzeichnis ausblenden]